Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Status

NO_LONGER_AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT02375464

Enrollment

Unknown

Registered

2015-03-02

Start date

2015-04-30

Completion date

2019-12-31

Last updated

2016-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroendocrine Tumors

Keywords

neuroendocrine tumor, carcinoid tumor

Brief summary

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

Detailed description

Patients with NETs will be evaluated by their own physicians. Before doing the PET scan using Gallium-68 DOTATOC, the physicians will be asked to describe the type of treatment that they would recommend. After the test is performed and the result reviewed, the physician will be asked to reevaluate the therapeutic and management options. Data will be analyzed to determine the impact of the testing on patient management. Gallium-68 has been designated an orphan drug due to the relative rarity of NETs. It is expected that the data collected from this and other similar trials will be used to provide data to the FDA regarding the safety and efficacy of this drug as an imaging agent for NETs and ultimately lead to FDA approval.

Interventions

DRUGGallium-68 DOTATOC

Imaging with Gallium-68 DOTATOC

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Proven or suspected neuroendocrine tumor Physician referral for imaging

Exclusion criteria

* Pregnancy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026